A New Vaccine Targeting the S1 of the S Protein Induce Mice Immune Response against COVID-19

Abstract

Coronavirus disease 2019 is pandemic across the world since the severe acute respiratory coronavirus-2 emerged in December 2019. The most efficient method to defend COVID 19 is vaccine. Here, we used HEK293 cell line to produce the recombinant protein and compared several vaccine candidates’ efficiency. The structures of the candidates were designed based on the S1 protein and RBD region. After three doses, the vaccines induced SARS-CoV-2 specific neutralizing antibodies in mice which presented high titers. The maximum neutralization activity could reach more than 90% without inflammation suggesting the great neutralizing ability against SARS-CoV-2. Significance statement: The COVID-19 has threatened human beings since 2019. This paper reveals a new recombinant protein vaccine that could induce mice immunity against the coronavirus. It compared the efficacy of different potential vaccines expressed by human embryonic kidney 293 cell. It showed the difference of them and helps people learn more about the COVID-19 subunit vaccines.